Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

References

• Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003; 42: 620–33
   PubMed Web of Science ®Google Scholar
• Roland S. Calcium studies in ten cases of osteoblastic prostatic metastases. J Urol 1958; 79: 339–42
   PubMedGoogle Scholar
• Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74–80
   PubMedGoogle Scholar
• Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68
   PubMed Web of Science ®Google Scholar
• Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002; 1: 145–152
   PubMedGoogle Scholar
• Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294–5297
   PubMed Web of Science ®Google Scholar
• Coxon FP, Benford HL, Russell RG, Rogers MJ. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 1998; 54: 631–8
   PubMedGoogle Scholar
• Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170: 246–52
   PubMed Web of Science ®Google Scholar
• Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 220–9
   PubMed Web of Science ®Google Scholar
• Shipman CM, Rogers MJ, Apperley J, Graham R, Russell G, Croucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma 1998; 32: 129–38
   PubMed Web of Science ®Google Scholar
• Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G, Croucher PI. Bisphosphonates––mechanisms of action in multiple myeloma. Acta Oncol 2000; 39: 829–35
   PubMed Web of Science ®Google Scholar
• Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211–21
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459–68
   PubMed Web of Science ®Google Scholar
• Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521–8; discussion 528–9.
   Google Scholar
• Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8
   PubMed Web of Science ®Google Scholar
• Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295–306
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate zoledronic acid induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–34
   PubMed Web of Science ®Google Scholar
• Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel zoledronic acid and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003; 26: S92–97
   Web of Science ®Google Scholar
• Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000; 14: 841–4
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, De Wit R, Berry W, et al A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone refractory prostate cancer(HRPC), ASCO Abstract 4 Genitourinary cancer category prostate cancer subcategory 2004.
   Google Scholar
• Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177–85
   PubMed Web of Science ®Google Scholar
• Carlin BI, Andriole GL. The natural history skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989–94
   PubMedGoogle Scholar
• Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–82
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997; 80: 1652–60
   PubMed Web of Science ®Google Scholar
• Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998; 38: 375–88
   PubMed Web of Science ®Google Scholar
• Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates osteoclasts and bone. Calcif Tissue Int 1991; 49: 407–15
   PubMed Web of Science ®Google Scholar
• Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698–705
   PubMed Web of Science ®Google Scholar
• Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890–4
   PubMed Web of Science ®Google Scholar
• Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37: 285–90
   PubMed Web of Science ®Google Scholar
• Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528–35
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653–61
   PubMed Web of Science ®Google Scholar
• Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action, alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095–105
   PubMed Web of Science ®Google Scholar
• O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind placebo-controlled dose–response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995; 13: 929–34
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785–91
   PubMed Web of Science ®Google Scholar
• Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 57–63
   Google Scholar
• Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek AY, et al. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 2004; 94: 524–7
   PubMed Web of Science ®Google Scholar